ArticleDiabetes care2011
Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide.
Article in Diabetes care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00305344 (Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children With Type 1 Diabetes - A Pilot Study), which is not on this map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children With Type 1 Diabetes - A Pilot Study
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: a systematic review and meta-analysis.Systematic reviews · 2022Pooled it
- Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study.Stem cell research & therapy · 2020Pooled it
- Pooled it
- Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Trial
- Immune profiling shows limited systemic changes in children with autism after autologous cord blood transfusion.Frontiers in immunology · 2026Article
- Umbilical cord blood derived cell expansion: a potential neuroprotective therapy.Stem cell research & therapy · 2024Review
- Review
- Umbilical cord mesenchymal stromal cells transplantation delays the onset of hyperglycemia in the RIP-B7.1 mouse model of experimental autoimmune diabetes through multiple immunosuppressive and anti-inflammatory responses.Frontiers in cell and developmental biology · 2023Article
- High Integrity and Fidelity of Long-Term Cryopreserved Umbilical Cord Blood for Transplantation.Journal of clinical medicine · 2021Article
- The Future State of Newborn Stem Cell Banking.Journal of clinical medicine · 2019Article
- Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?Frontiers in immunology · 2019Review
- Stem cell transplantation for the treatment of patients with type 1 diabetes mellitus: A meta-analysis.Experimental and therapeutic medicine · 2018Article
- (Re)generating Human Beta Cells: Status, Pitfalls, and Perspectives.Physiological reviews · 2018Review
- Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits.Stem cell investigation · 2018Article
- Eminent Sources of Adult Mesenchymal Stem Cells and Their Therapeutic Imminence.Stem cell reviews and reports · 2017Review
- Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy.Molecular therapy. Methods & clinical development · 2017Article
- Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes.Stem cells (Dayton, Ohio) · 2016Review
- Article
- Umbilical cord blood donation: public or private?Bone marrow transplantation · 2015Review
- The role and potential of umbilical cord blood in an era of new therapies: a review.Stem cell research & therapy · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
objectiveWe conducted an open-label, phase I study using autologous umbilical cord blood (UCB) infusion to ameliorate type 1 diabetes (T1D). Having previously reported on the first 15 patients reaching 1 year of follow-up, herein we report on the complete cohort after 2 years of follow-up. RESEARCH DESIGN AND
methodsA total of 24 T1D patients (median age 5.1 years) received a single intravenous infusion of autologous UCB cells and underwent metabolic and immunologic assessments.
resultsNo infusion-related adverse events were observed. β-Cell function declined after UCB infusion. Area under the curve C-peptide was 24.3% of baseline 1 year postinfusion (P < 0.001) and 2% of baseline 2 years after infusion (P < 0.001). Flow cytometry revealed increased regulatory T cells (Tregs) (P = 0.04) and naive Tregs (P = 0.001) 6 and 9 months after infusion, respectively.
conclusionsAutologous UCB infusion in children with T1D is safe and induces changes in Treg frequency but fails to preserve C-peptide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.